United StatesÚltimas notícias

Elliptic claims Iran’s central bank used stablecoins to quietly build a $500 million sanctions-resistant reserve.

Bitcoin and Ether ETFs recorded major outflows as global macro risks drove institutional caution.

Netflix just crossed 325 million subscribers and beat revenue with $12.1 billion in Q4, yet its stock slid as markets focused elsewhere.

Lexicon Pharmaceuticals (NASDAQ:LXRX) successfully completed an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration for its lead pain candidate, pilavapadin.

City Holding Company (NASDAQ:CHCO) capped a historic 2025 with record annual net income of $130.5 million, as the West Virginia-based lender defied industry-wide margin pressures through robust loan growth and stellar efficiency.

Dr. Reddy’s Laboratories (NYSE:RDY) reported fiscal third-quarter revenue that surpassed analyst expectations Wednesday, as explosive growth in emerging markets and a resilient domestic business in India helped offset a steep decline in its North American generic portfolio.

Truist Financial (NYSE:TFC) reported fourth-quarter adjusted earnings that cleared Wall Street hurdles, supported by a significant $10 billion share repurchase authorization and expanding margins.

Greene County Bancorp (NASDAQ:GCBC) reported a surge in profitability, achieving the highest quarterly and six-month earnings in its 137-year history.

Smithfield Foods (NASDAQ:SFD) announced Wednesday that it will acquire iconic hot dog maker Nathan’s Famous (NASDAQ:NATH) in an all-cash transaction valued at $102 per share, or approximately $450 million in enterprise value.

Beneficient (NASDAQ:BENF) shares are in focus Wednesday after a federal court granted final approval to a binding settlement resolving all claims related to the collapse of GWG Holdings against the company and its leadership.

Revelation Biosciences (NASDAQ:REVB) announced it has reached a milestone agreement with the FDA on an "expedient" approval pathway for Gemini, its lead candidate for the treatment of Acute Kidney Injury (AKI).

Lisata Therapeutics (NASDAQ:LSTA) shares soared Wednesday morning after the clinical-stage biotech announced a binding agreement to be acquired by privately held Kuva Labs.